These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24371775)
21. Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. Grossman M; Ruan J; Magro C JAAD Case Rep; 2022 Jul; 25():58-62. PubMed ID: 35755174 [No Abstract] [Full Text] [Related]
22. Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report. Hu P; Ben Y; Liu J; Zheng W; Yan X; Zhang Y; Shi W Onco Targets Ther; 2021; 14():2489-2495. PubMed ID: 33883903 [TBL] [Abstract][Full Text] [Related]
23. Sequential development of diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. Huang J; Zhang PH; Gao YH; Qiu LG Diagn Cytopathol; 2012 Apr; 40(4):346-51. PubMed ID: 21472868 [TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas. Chen YP; Jones D; Chen TY; Chang KC Leuk Lymphoma; 2014 Sep; 55(9):2038-47. PubMed ID: 24180328 [TBL] [Abstract][Full Text] [Related]
25. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Beltran BE; Quiñones P; Morales D; Malaga JM; Chavez JC; Sotomayor EM; Castillo JJ Hematol Oncol; 2018 Feb; 36(1):93-97. PubMed ID: 28639256 [TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study. Bingjie W; Lihong W; Yongjin S; Huihui L; Jinping O; Xi'nan C Hematol Oncol; 2020 Aug; 38(3):272-276. PubMed ID: 32083758 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Ahn JS; Yang DH; Duk Choi Y; Jung SH; Yhim HY; Kwak JY; Sung Park H; Shin MG; Kim YK; Kim HJ; Lee JJ Am J Hematol; 2013 Sep; 88(9):774-9. PubMed ID: 23760676 [TBL] [Abstract][Full Text] [Related]
35. Angioimmunoblastic T-Cell Lymphoma: A Case Report. Miles B; Bazuaye-Ekwuyasi EA; Mallick J; Nguyen QD Cureus; 2022 May; 14(5):e25526. PubMed ID: 35800798 [TBL] [Abstract][Full Text] [Related]
36. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393 [TBL] [Abstract][Full Text] [Related]
37. Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. Oishi N; Sartori-Valinotti JC; Bennani NN; Wada DA; He R; Cappel MA; Feldman AL J Cutan Pathol; 2019 Sep; 46(9):637-644. PubMed ID: 30980412 [TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma. Poon F; Ieremia E; Collins G; Matin RN Am J Dermatopathol; 2019 Dec; 41(12):927-930. PubMed ID: 31599749 [TBL] [Abstract][Full Text] [Related]
39. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Attygalle AD; Chuang SS; Diss TC; Du MQ; Isaacson PG; Dogan A Histopathology; 2007 Mar; 50(4):498-508. PubMed ID: 17448026 [TBL] [Abstract][Full Text] [Related]